Skip to main content
SpringerLink
Log in

Gastrointestinal Lymphomas

  • Chapter
  • First Online:
Textbook of Gastrointestinal Oncology

  • 863 Accesses

Abstract

Primary gastrointestinal (GI) lymphomas constitute 1–4% of all gastrointestinal malignancies, and 90% are of B-cell type. The most commonly involved sites are as follows: stomach (60–75%), small intestine (9%), ileocecal region (7%), and colorectal region (<1%). Certain histological subtypes of lymphomas may preferentially involve specific sites in the gastrointestinal tract. There are several known risk factors for the development of primary GI lymphoma. Pretreatment work-up and tissue biopsy are necessary for definitive diagnosis and evaluation of the extent of the disease. There is limited consensus on the staging system of primary GI lymphoma, with three staging systems in use: Ann-Arbor staging with Musshoff modification, Lugano staging system, and Paris staging system. The treatment depends upon the patient’s clinical condition, histological subtype, and stage of the disease and may range from observation to stem cell transplantation. This chapter will focus on the most common primary GI lymphomas of the stomach, small intestine, and colon and extranodal involvement of the GI tract by systemic lymphomas. Epidemiology, etiology, risk factors, diagnostic procedures, staging, treatment, and follow-up of GI lymphomas will be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Paryani S, Hoppe RT, Burke JS, Sneed P, Dawley D, Cox RS, et al. Extralymphatic involvement in diffuse non-Hodgkin’s lymphoma. J Clin Oncol. 1983;1(11):682–8.

    Article  CAS  PubMed  Google Scholar 

  2. Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer. 1972;29:252–60.

    Article  CAS  PubMed  Google Scholar 

  3. Loehr WJ, Mujahed Z, Zahn FD, Gray GF, Thorbjarnarson B. Primary lymphoma of the gastrointestinal tract: a review of 100 cases. Ann Surg. 1969;170(2):232–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Gurney KA, Cartwright RA. Increasing incidence and descriptive epidemiology of extranodal non-Hodgkin lymphoma in parts of England and Wales. Hematol J. 2002;3(2):95–104.

    Article  PubMed  Google Scholar 

  5. Dawson IM, Cornes JS, Morson BC. Primary malignant lymphoid tumors of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. Br J Surg. 1961;49:80.

    Article  CAS  PubMed  Google Scholar 

  6. Lewin KJ, Ranchod M, Dorfman RF. Lymphomas of the gastrointestinal tract: a study of 117 cases presenting with gastrointestinal disease. Cancer. 1978;42:693.

    Article  CAS  PubMed  Google Scholar 

  7. Koch P, del Valle F, Berdel WE, Willich NA, Reers B, Hiddemann W, et al; German Multicenter Study Group. Primary gastrointestinal non-Hodgkin’s lymphoma: I. Anatomic and histologic distribution, clinical features, and survival data of 371 patients registered in the German Multicenter Study GIT NHL 01/92. J Clin Oncol. 2001;19(18):3861–73.

    Google Scholar 

  8. Papaxoinis G, Papageorgiou S, Rontogianni D, Kaloutsi V, Fountzilas G, Pavlidis N, et al. Primary gastrointestinal non-Hodgkin’s lymphoma: a clinicopathologic study of 128 cases in Greece. A Hellenic Cooperative Oncology Group study (HeCOG). Leuk Lymphoma. 2006;47(10):2140–6.

    Article  PubMed  Google Scholar 

  9. Cogliatti SB, Schmid U, Schumacher U, Eckert F, Hansmann ML, Hedderich J, et al. Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology. 1991;101:1159–70.

    Article  CAS  PubMed  Google Scholar 

  10. Müller AM, Ihorst G, Mertelsmann R, Engelhardt M. Epidemiology of non-Hodgkin’s lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol. 2005;84:1–12.

    Article  PubMed  Google Scholar 

  11. Brands F, Monig SP, Raab M. Treatment and prognosis of gastric lymphoma. Eur J Surg. 1997;163:803–13.

    CAS  PubMed  Google Scholar 

  12. Zucca E, Bertoni F, Roggero E, Bosshard G, Cazzaniga G, Pedrinis E, et al. Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. N Engl J Med. 1998;338:804–10.

    Article  CAS  PubMed  Google Scholar 

  13. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG. Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet. 1991;338:1175.

    Article  CAS  PubMed  Google Scholar 

  14. Aull MJ, Buell JF, Peddi VR, Trofe J, Beebe TM, Hanaway MJ, et al; Israel Penn International Transplant Tumor Registry. MALToma: a Helicobacter pylori-associated malignancy in transplant patients: a report from the Israel Penn International Transplant Tumor Registry with a review of published literature. Transplantation. 2003;75(2):225–8.

    Article  PubMed  Google Scholar 

  15. McTamaney JP, Neifeld JP, Mendez-Picon G, Lee HM. Primary gastric lymphoma following renal transplantation. J Surg Oncol. 1981;18:265.

    Article  CAS  PubMed  Google Scholar 

  16. Heise W, Arastéh K, Mostertz P, Skörde J, Schmidt W, Obst C, et al. Malignant gastrointestinal lymphomas in patients with AIDS. Digestion. 1997;58:218.

    Article  CAS  PubMed  Google Scholar 

  17. Whooley BP, Bernik S, Sarkis AY, Wallack MK. Primary gastrointestinal non-Hodgkin’s lymphoma: increasingly AIDS-related. Am Surg. 1998;64:137.

    CAS  PubMed  Google Scholar 

  18. Andrews CN, John Gill M, Urbanski SJ, Stewart D, Perini R, Beck P. Changing epidemiology and risk factors for gastrointestinal non-Hodgkin’s lymphoma in a North American population: population-based study. Am J Gastroenterol. 2008;103:1762.

    Article  PubMed  Google Scholar 

  19. Catassi C, Fabiani E, Corrao G, Barbato M, De Renzo A, Carella AM, et al. Risk of non-Hodgkin lymphoma in celiac disease. JAMA. 2002;287:1413.

    Article  PubMed  Google Scholar 

  20. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Geborek P, Bladström A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumor necrosis factor blockers do not increase overall tumor risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis. 2005;64(5):699–703.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheum. 2006;54(3):692–701.

    Article  PubMed  Google Scholar 

  23. Mathus-Vliegen EMH, Van Halteren H, Tytgat GNJ. Malignant lymphoma in coeliac disease: various manifestations with distinct symptomatology and prognosis? J Intern Med. 1994;236:43–9.

    Article  CAS  PubMed  Google Scholar 

  24. Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated lymphoid tissue: factors relevant to prognosis. Gastroenterology. 1992;102:1628.

    Article  CAS  PubMed  Google Scholar 

  25. Wang T, Gui W, Shen Q. Primary gastrointestinal non-Hodgkin’s lymphoma: clinicopathological and prognostic analysis. Med Oncol. 2010;27:661.

    Article  PubMed  Google Scholar 

  26. Caletti G, Ferrari A, Brocchi E, Barbara L. Accuracy of endoscopic ultrasonography in the diagnosis and staging of gastric cancer and lymphoma. Surgery. 1993;113:14.

    CAS  PubMed  Google Scholar 

  27. Fujishima H, Misawa T, Maruoka A, Chijiiwa Y, Sakai K, Nawata H. Staging and follow-up of primary gastric lymphoma by endoscopic ultrasonography. Am J Gastroenterol. 1991;86:719.

    CAS  PubMed  Google Scholar 

  28. Vilmann P, Hancke S, Henriksen FW, Jacobsen GK. Endoscopic ultrasonography-guided fine-needle aspiration biopsy of lesions in the upper gastrointestinal tract. Gastrointest Endosc. 1995;41:230.

    Article  CAS  PubMed  Google Scholar 

  29. Spinelli P, Lo Gullo C, Pizzetti P. Endoscopic diagnosis of gastric lymphomas. Endoscopy. 1980;12:211.

    Article  CAS  PubMed  Google Scholar 

  30. Fork FT, Haglund U, Högström H, Wehlin L. Primary gastric lymphoma versus gastric cancer. An endoscopic and radiographic study of differential diagnostic possibilities. Endoscopy. 1985;17:5.

    Article  CAS  PubMed  Google Scholar 

  31. Suekane H, Iida M, Yao T, Matsumoto T, Masuda Y, Fujishima M. Endoscopic ultrasonography in primary gastric lymphoma: correlation with endoscopic and histologic findings. Gastrointest Endosc. 1993;39:139–45.

    Article  CAS  PubMed  Google Scholar 

  32. Novak U, Basso K, Pasqualucci L, Dalla-Favera R, Bhagat G. Genomic analysis of non-splenic marginal zone lymphomas (MZL) indicates similarities between nodal and extranodal MZL and supports their derivation from memory B-cells. Br J Haematol. 2011;155:362.

    Article  CAS  PubMed  Google Scholar 

  33. Nakamura S, Matsumoto T, Nakamura S, Jo Y, Fujisawa K, Suekane H, Yao T, Tsuneyoshi M, Iida M. Chromosomal translocation t(11;18)(q21;q21) in gastrointestinal mucosa associated lymphoid tissue lymphoma. J Clin Pathol. 2003;56:36–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Bertoni F, Zucca E. Delving deeper into MALT lymphoma biology. J Clin Invest. 2006;116:22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Dierlamm J, Baens M, Wlodarska I, Stefanova-Ouzounova M, Hernandez JM, Hossfeld DK, et al. The apoptosis inhibitor gene API2 and a novel 18q gene, MLT, are recurrently rearranged in the t(11;18) (q21;q21) associated with mucosa-associated lymphoid tissue lymphomas. Blood. 1999;93:3601–9.

    CAS  PubMed  Google Scholar 

  36. Yeh KH, Kuo SH, Chen LT, Mao TL, Doong SL, Wu MS, et al. Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood. 2005;106:1037–41.

    Article  CAS  PubMed  Google Scholar 

  37. Park YH, Kim WS, Bang SM, Lee SI, Uhm JE, Kang HJ, et al. Prognostic factor analysis and proposed prognostic model for conventional treatment of high-grade primary gastric lymphoma. Eur J Haematol. 2006;77:304–8.

    Article  PubMed  Google Scholar 

  38. Klapproth K, Wirth T. Advances in the understanding of MYC-induced lymphomagenesis. Br J Haematol. 2010;149:484–97.

    Article  CAS  PubMed  Google Scholar 

  39. Iqbal J, Neppalli VT, Wright G, Dave BJ, Horsman DE, Rosenwald A, et al. BCL2 expression is a prognostic marker for the activated B-cell-like type of diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:961–8.

    Article  CAS  PubMed  Google Scholar 

  40. Johnson NA, Slack GW, Savage KJ, Connors JM, Ben-Neriah S, Rogic S, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3452–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Perry C, Herishanu Y, Metzer U, Bairey O, Ruchlemer R, Trejo L, et al. Diagnostic accuracy of PET/CT in patients with extranodal marginal zone MALT lymphoma. Eur J Haematol. 2007;79:205.

    Article  PubMed  Google Scholar 

  42. Zucca E, Copie-Bergman C, Ricardi U, Thieblemont C, Raderer M, Ladetto M, Ladetto M, ESMO Guidelines Working Group. Gastric marginal zone lymphoma of MALT type: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi144–8.

    Article  PubMed  Google Scholar 

  43. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059–68.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Musshoff K, Schmidt-Vollmer H. Proceedings: prognosis of non-Hodgkin’s lymphomas with special emphasis on the staging classification. Z Krebsforsch Klin Onkol Cancer Res Clin Oncol. 1975;83(4):323–41.

    Article  CAS  PubMed  Google Scholar 

  45. Rohatiner A, d’Amore F, Coiffier B, Crowther D, Gospodarowicz M, Isaacson P, et al. Report on a workshop convened to discuss the pathological and staging classifications of gastrointestinal tract lymphoma. Ann Oncol. 1994;5(5):397–400.

    Article  CAS  PubMed  Google Scholar 

  46. Ruskoné-Fourmestraux A, Dragosics B, Morgner A, Wotherspoon A, De Jong D. Paris staging system for primary gastrointestinal lymphomas. Gut. 2003;52(6):912–3.

    Article  PubMed  PubMed Central  Google Scholar 

  47. Inagaki H, Nakamura T, Li C, Sugiyama T, Asaka M, Kodaira J, et al. Gastric MALT lymphomas are divided into three groups based on responsiveness to Helicobacter Pylori eradication and detection of API2-MALT1 fusion. Am J Surg Pathol. 2004;28:1560–7.

    Article  PubMed  Google Scholar 

  48. Xia B, Zhang L, Guo SQ, Li XW, Qu FL, Zhao HF, et al. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma. World J Gastroenterol. 2015;21:2433–42.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Nakamura S, Sugiyama T, Matsumoto T, Iijima K, Ono S, Tajika M, et al. Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut. 2012;61:507–13.

    Article  PubMed  Google Scholar 

  50. Alpen B, Neubauer A, Dierlamm J, Marynen P, Thiede C, Bayerdörfer E, et al. Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type responding to eradication of Helicobacter pylori infection. Blood. 2000;95:4014–5.

    CAS  PubMed  Google Scholar 

  51. Neubauer A, Thiede C, Morgner A, Alpen B, Ritter M, Neubauer B, et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst. 1997;89:1350–5.

    Article  CAS  PubMed  Google Scholar 

  52. Conconi A, Martinelli G, Thiéblemont C, Ferreri AJ, Devizzi L, Peccatori F, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741–5.

    Article  CAS  PubMed  Google Scholar 

  53. Martinelli G, Laszlo D, Ferreri AJ, Pruneri G, Ponzoni M, Conconi A, et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin’s lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol. 2005;23:1979–83.

    Article  CAS  PubMed  Google Scholar 

  54. Raderer M, Streubel B, Wöhrer S, Häfner M, Chott A. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut. 2006;55:616–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Daum S, Ullrich R, Heise W, Dederke B, Foss HD, Stein H, et al. Intestinal non-Hodgkin’s lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin’s Lymphoma. J Clin Oncol. 2003;21:2740–6.

    Article  PubMed  Google Scholar 

  56. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, et al. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet. 1993;342:575–7.

    Article  CAS  PubMed  Google Scholar 

  57. Shiozawa E, Norose T, Kaneko K, Yamochi-Onizuka T, Takimoto M, Imawari M, et al. Clinicopathological comparison of the World Health Organization/Wotherspoon score to the Grouped’Etude des Lymphomes de l’Adult grade for the post-treatment evaluation of gastric mucosa-associated lymphoid tissue lymphoma. J Gastroenterol Hepatol. 2009;24:307–15.

    Article  PubMed  Google Scholar 

  58. Ruskoné-Fourmestraux A, Fischbach W, Aleman BM, Boot H, Du MQ, Megraud F, EGILS group. EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT. Gut. 2011;60:747–58.

    Article  PubMed  Google Scholar 

  59. Zucca E, Dreyling M, ESMO Guideline Working Group. Gastric marginal zone lymphoma of MALT type: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:175–6.

    Article  Google Scholar 

  60. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.

    Article  PubMed  Google Scholar 

  61. Schottenfeld D, Beebe-Dimmer JL, Vigneau FD. The epidemiology and pathogenesis of neoplasia in the small intestine. Ann Epidemiol. 2009;19(1):58–69.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Isaacson PG. Gastrointestinal lymphoma. Hum Pathol. 1994;25(10):1020–9.

    Article  CAS  PubMed  Google Scholar 

  63. Al-Saleem T, Al-Mondhiry H. Immunoproliferative small intestinal disease (IPSID): a model for mature B-cell neoplasms. Blood. 2005;105(6):2274–80.

    Article  CAS  PubMed  Google Scholar 

  64. Bibas M, Antinori A. EBV and HIV-Related Lymphoma. Mediterr J Hematol Infect Dis. 2009;1(2):e2009032.

    PubMed  PubMed Central  Google Scholar 

  65. Delabie J, Holte H, Vose JM, Ullrich F, Jaffe ES, Savage KJ, et al. Enteropathy-associated T-cell lymphoma: clinical and histological findings from the international peripheral T-cell lymphoma project. Blood. 2011;118(1):148–55.

    Article  CAS  PubMed  Google Scholar 

  66. Quintanilla-Martinez L, Lome-Maldonado C, Ott G, Gschwendtner A, Gredler E, Angeles-Angeles A, et al. Primary intestinal non-Hodgkin’s lymphoma and Epstein-Barr virus: high frequency of EBV-infection in T-cell lymphomas of Mexican origin. Leuk Lymphoma. 1998;30(1–2):111–21.

    Article  CAS  PubMed  Google Scholar 

  67. Lecuit M, Abachin E, Martin A, Poyart C, Pochart P, Suarez F, Bengoufa D, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med. 2004;350(3):239–48.

    Article  CAS  PubMed  Google Scholar 

  68. Nikbin B, Banisadre M, Ala F, Mojtabai A. HLA AW19, B12 in immunoproliferative small intestinal disease. Gut. 1979;20(3):226–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  69. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91(4):854–62.

    Article  CAS  PubMed  Google Scholar 

  70. Cooper BT, Holmes GK, Ferguson R, Cooke WT. Celiac disease and malignancy. Medicine (Baltimore). 1980;59(4):249–61.

    Article  CAS  Google Scholar 

  71. Asano N, Kato S, Nakamura S. Epstein-Barr virus-associated natural killer/T-cell lymphomas. Best Pract Res Clin Haematol. 2013;26(1):15–21.

    Article  CAS  PubMed  Google Scholar 

  72. Heise W. GI-lymphomas in immunosuppressed patients (organ transplantation; HIV). Best Pract Res Clin Gastroenterol. 2010;24(1):57–69.

    Article  PubMed  Google Scholar 

  73. Castellano G, Moreno D, Galvao O, Ballestín C, Colina F, Mollejo M, et al. Malignant lymphoma of jejunum with common variable hypogammaglobulinemia and diffuse nodular hyperplasia of the small intestine. A case study and literature review. J Clin Gastroenterol. 1992;15(2):128–35.

    Article  CAS  PubMed  Google Scholar 

  74. Ghai S, Pattison J, Ghai S, O’Malley ME, Khalili K, Stephens M. Primary gastrointestinal lymphoma: spectrum of imaging findings with pathologic correlation. Radiographics. 2007;27(5):1371–88.

    Article  PubMed  Google Scholar 

  75. Juweid M, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571–8.

    Article  PubMed  Google Scholar 

  76. Cronin CG, Scott J, Kambadakone A, Catalano OA, Sahani D, Blake MA, et al. Utility of positron emission tomography/CT in the evaluation of small bowel pathology. Br J Radiol. 2012;85(1017):1211–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Chung HH, Kim YH, Kim JH, Cha SH, Kim BH, Kim TK, et al. Imaging findings of mantle cell lymphoma involving gastrointestinal tract. Yonsei Med J. 2003;44(1):49–57.

    Article  PubMed  Google Scholar 

  78. Schmatz AI, Streubel B, Kretschmer-Chott E, Püspök A, Jäger U, Mannhalter C, et al. Primary follicular lymphoma of the duodenum is a distinct mucosal/submucosal variant of follicular lymphoma: a retrospective study of 63 cases. J Clin Oncol. 2011;29(11):1445–51.

    Article  PubMed  Google Scholar 

  79. Joyce AM, Burns DL, Marcello PW, Tronic B, Scholz FJ. Capsule endoscopy findings in celiac disease associated enteropathy-type intestinal T-cell lymphoma. Endoscopy. 2005;37(6):594–6.

    Article  CAS  PubMed  Google Scholar 

  80. Yamamoto S, Nakase H, Yamashita K, Matsuura M, Takada M, Kawanami C, et al. Gastrointestinal follicular lymphoma: review of the literature. J Gastroenterol. 2010;45(4):370–88.

    Article  PubMed  Google Scholar 

  81. Al-Saleem TI, Qadiry WA, Issa FS, King J. The immunoselection technic in laboratory diagnosis of alpha heavy-chain disease. Am J Clin Pathol. 1979;72(1):132–3.

    Article  CAS  PubMed  Google Scholar 

  82. Suzuki R. NK/T-cell lymphomas: pathobiology, prognosis and treatment paradigm. Curr Oncol Rep. 2012;14(5):395–402.

    Article  CAS  PubMed  Google Scholar 

  83. Kim SJ, Kang HJ, Kim JS, Oh SY, Choi CW, Lee SI, et al. Comparison of treatment strategies for patients with intestinal diffuse large B-cell lymphoma: surgical resection followed by chemotherapy versus chemotherapy alone. Blood. 2011;117(6):1958–65.

    Article  CAS  PubMed  Google Scholar 

  84. Aleman BM, Haas RL, van der Maazen RW. Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2010;24(1):27–34.

    Article  PubMed  Google Scholar 

  85. Azab MB, Henry-Amar M, Rougier P, Bognel C, Theodore C, Carde P, et al. Prognostic factors in primary gastrointestinal non-Hodgkin’s lymphoma. A multivariate analysis, report of 106 cases, and review of the literature. Cancer. 1989;64(6):1208–17.

    Article  CAS  PubMed  Google Scholar 

  86. Ben-Ayed F, Halphen M, Najjar T, Boussene H, Jaafoura H, Bouguerra A, et al. Treatment of alpha chain disease. Results of a prospective study in 21 Tunisian patients by the Tunisian-French intestinal Lymphoma Study Group. Cancer. 1989;63(7):1251–6.

    Article  CAS  PubMed  Google Scholar 

  87. el Saghir NS. Combination chemotherapy with tetracycline and aggressive supportive care for immunoproliferative small-intestinal disease lymphoma. J Clin Oncol. 1995;13(3):794–5.

    Article  PubMed  Google Scholar 

  88. Shih L, Liaw SJ, Dunn P, Kuo TT. Primary small-intestinal lymphomas in Taiwan: immunoproliferative small-intestinal disease and nonimmunoproliferative small-intestinal disease. J Clin Oncol. 1994;12(7):1375–82.

    Article  CAS  PubMed  Google Scholar 

  89. Lee J, Kim WS, Kim K, Ahn JS, Jung CW, Lim HY, et al. Prospective clinical study of surgical resection followed by CHOP in localized intestinal diffuse large B cell lymphoma. Leuk Res. 2007;31(3):359–64.

    Article  PubMed  Google Scholar 

  90. Foon KA, Takeshita K, Zinzani PL. Novel therapies for aggressive B-cell lymphoma. Adv Hematol. 2012;2012:302570.

    PubMed  PubMed Central  Google Scholar 

  91. Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K, et al. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci. 2008;99(5):1016–20.

    Article  CAS  PubMed  Google Scholar 

  92. Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood. 2010;116(18):3418–25.

    Article  CAS  PubMed  Google Scholar 

  93. Sieniawski M, Angamuthu N, Boyd K, Chasty R, Davies J, Forsyth P, et al. Evaluation of enteropathy-associated T-cell lymphoma comparing standard therapies with a novel regimen including autologous stem cell transplantation. Blood. 2010;115(18):3664–70.

    Article  CAS  PubMed  Google Scholar 

  94. Nijeboer P, Malamut G, Mulder CJ, Cerf-Bensussan N, Sibon D, Bouma G, et al. Enteropathy-associated T-cell lymphoma: improving treatment strategies. Dig Dis. 2015;33(2):231–5.

    Article  CAS  PubMed  Google Scholar 

  95. Dionigi G, Annoni M, Rovera F, Boni L, Villa F, Castano P, et al. Primary colorectal lymphomas: review of the literature. Surg Oncol. 2007;16(Suppl 1):S169–71.

    Article  PubMed  Google Scholar 

  96. Kim YH, Lee JH, Yang SK, Kim TI, Kim JS, Kim HJ, et al. Primary colon lymphoma in Korea: a KASID (Korean Association for the Study of Intestinal Diseases) Study. Dig Dis Sci. 2005;50(12):2243–7.

    Article  PubMed  Google Scholar 

  97. Doolabh N, Anthony T, Simmang C, Bieligk S, Lee E, Huber P, et al. Primary colonic lymphoma. J Surg Oncol. 2000;74(4):257–62.

    Article  CAS  PubMed  Google Scholar 

  98. Yu H, Wang Y, Peng L, Lia A, Zhang Y. Endoscopic manifestations of primary colorectal lymphoma. Hepato-Gastroenterology. 2014;61(129):76–8.

    PubMed  Google Scholar 

  99. Mendelson RM, Fermoyle S. Primary gastrointestinal lymphomas: a radiological-pathological review. Part 1: stomach, oesophagus and colon. Australas Radiol. 2005;49(5):353–64.

    Article  CAS  PubMed  Google Scholar 

  100. Koniaris LG, Drugas G, Katzman PJ, Salloum R. Management of gastrointestinal lymphoma. J Am Coll Surg. 2003;197(1):127–41.

    Article  PubMed  Google Scholar 

  101. Maddocks K, Blum KA. Treatment strategies in mantle cell lymphoma. Cancer Treat Res. 2015;165:251–70.

    Article  PubMed  Google Scholar 

  102. Stanojevic GZ, Nestorovic MD, Brankovic BR, Stojanovic MP, Jovanovic MM, Radojkovic MD. Primary colorectal lymphoma: an overview. World J Gastrointest Oncol. 2011;3(1):14–8.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Ghimire P, Wu GY, Zhu L. Primary gastrointestinal lymphoma. World J Gastroenterol. 2011;17:697–707.

    Article  PubMed  PubMed Central  Google Scholar 

  104. Arora N, Manipadam MT, Pulimood A, Ramakrishna BS, Chacko A, Kurian SS, et al. Gastrointestinal lymphomas: pattern of distribution and histological subtypes: 10 years experience in a tertiary centre in South India. Indian J Pathol Microbiol. 2011;54(4):712–9.

    PubMed  Google Scholar 

  105. Vetro C, Romano A, Amico I, Conticello C, Motta G, Figuera A, et al. Endoscopic features of gastro-intestinal lymphomas: from diagnosis to follow-up. World J Gastroenterol. 2014;20(36):12993–3005.

    Article  PubMed  PubMed Central  Google Scholar 

  106. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood. 2006;107:265–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  107. Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116:3724–34.

    Article  CAS  PubMed  Google Scholar 

  108. Warrick J, Luo J, Robirds D, Branson J, Frater JL, Kreisel F, et al. Gastrointestinal lymphomas in a North American population: clinicopathologic features from one major Central-Midwestern United States tertiary care medical center. Diagn Pathol. 2012;28(7):76.

    Article  Google Scholar 

  109. Ekstrom-Smedby K. Epidemiology and etiology of Non-Hodgkin lymphoma: a review. Acta Oncol. 2006;45:258–71.

    Article  PubMed  Google Scholar 

  110. Solal-Céligny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258–65.

    Article  CAS  PubMed  Google Scholar 

  111. Aschebrook-Kilfoy B, Caces DB, Ollberding NJ, Smith SM, Chiu BC. An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA. Leuk Lymphoma. 2013;54(8):1677–83.

    Article  PubMed  Google Scholar 

  112. Romaguera JE, Medeiros LJ, Hagemeister FB, Fayad LE, Rodriguez MA, Pro B, et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer. 2003;97:586–91.

    Article  PubMed  Google Scholar 

  113. Salar A, Juanpere N, Bellosillo B, Domingo-Domenech E, Espinet B, Seoane A, et al. Gastrointestinal involvement in mantle cell lymphoma: a prospective clinic, endoscopic, and pathologic study. Am J Surg Pathol. 2006;30:1274–80.

    Article  PubMed  Google Scholar 

  114. Ruskoné-Fourmestraux A, Delmer A, Lavergne A, Molina T, Brousse N, Audouin J, et al. Multiple lymphomatous polyposis of the gastrointestinal tract: prospective clinicopathologic study of 31 cases. Groupe D’étude des Lymphomes Digestifs. Gastroenterology. 1997;112(1):7–16.

    Article  PubMed  Google Scholar 

  115. Leoncini L, et al. Burkitt lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARC; 2008. p. 262–4.

    Google Scholar 

  116. Hartge P, Wang S. Overview of the etiology and epidemiology of lymphoma. In: Mauch PMAJOCB, Dalla-Favera R, Harris NL, editors. Non-Hodgkin’s lymphomas. New York: Lippincott, Williams andWilkins; 2004. p. 711–27.

    Google Scholar 

  117. Vianna NJ. The malignant lymphomas: epidemiology and related aspects. Pathobiology Annual. 1977;7:231–55.

    CAS  PubMed  Google Scholar 

  118. Raphael M, Said J, Borisch B, Cesarman E, Harris NL. Lymphomas associated with HIV infection. In: Swerdlow SH, Campo E, HarrisNL JES, Pileri SA, Stein H, et al., editors. WHO classification oftumors of haematopoietic and lymphoid tissues. 4th ed. Lyon: IARCPress; 2008. p. 340–1.

    Google Scholar 

  119. Oyama T, Ichimura K, Suzuki R, Suzumiya J, Ohshima K, Yatabe Y, et al. Senile EBV+ B-cell lymphoproliferative disorders: a clin-icopathologic study of 22 patients. Am J Surg Pathol. 2003;27(1):16–26.

    Article  PubMed  Google Scholar 

  120. De Vita S, Sacco C, Sansonno D, Gloghini A, Dammacco F, Crovatto M, et al. Characterization of overt B-cell lymphomas in patients withhepatitis C virus infection. Blood. 1997;90(2):776–82.

    PubMed  Google Scholar 

  121. Wu W, Doan N, Said J, Karunasiri D, Pullarkat ST. Strong expression of chemokine receptor CCR9 in diffuse large B-cell lymphoma and follicular lymphoma strongly correlates with gastrointestinal involvement. Hum Pathol. 2014;45(7):1451–8.

    Article  CAS  PubMed  Google Scholar 

  122. Ma S. Risk Factors of Follicular Lymphoma. Expert Opin Med Diagn. 2012;6(4):323–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. De Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, et al. Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the International Lymphoma Epidemiology Consortium. Clin Gastroenterol Hepatol. 2008;6:451–8.

    Article  PubMed  PubMed Central  Google Scholar 

  124. Bertoni F, Rinaldi A, Zucca E, Cavalli F. Update on the molecular biology of mantle cell lymphoma. Hematol Oncol. 2006;24:22–7.

    Article  CAS  PubMed  Google Scholar 

  125. Orem J, Mbidde EK, Lambert B, de Sanjose S, Weiderpass E. Burkitt’s lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci. 2007;7(3):166–75.

    PubMed  PubMed Central  Google Scholar 

  126. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al; ESMO Guidelines Committee. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v116–25.

    Article  PubMed  Google Scholar 

  127. Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, et al. Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue. Blood. 2014;123:1214–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  128. Akasaka T, Lossos IS, Levy R. BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood. 2003;102:1443.

    Article  CAS  PubMed  Google Scholar 

  129. Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U, Ladetto M, ESMO Guidelines Working Group. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl 3):iii76–82.

    Article  PubMed  Google Scholar 

  130. Vose JM. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management. Am J Hematol. 2015;90(8):739–45.

    Article  CAS  PubMed  Google Scholar 

  131. Fernàndez V, Salamero O, Espinet B, Solé F, Royo C, Navarro A, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70:1408–18.

    Article  CAS  PubMed  Google Scholar 

  132. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin lymphoma staging classification. Cancer Res. 1971;31(11):1860–1.

    CAS  PubMed  Google Scholar 

  133. Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87(2):146–71.

    Article  PubMed  Google Scholar 

  134. Cheson BD. Role of functional imaging in the management of lym-phoma. J Clin Oncol. 2011;29(14):1844–54.

    Article  PubMed  Google Scholar 

  135. Miller TP. The limits of limited stage lymphoma. J Clin Oncol. 2004;22(15):2982–4.

    Article  PubMed  Google Scholar 

  136. Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113:6069–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  137. Hernandez-Ilizaliturri FJ, Deeb G, Zinzani PL, Pileri SA, Malik F, Macon WR, et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer. 2011;117:5058–66.

    Article  CAS  PubMed  Google Scholar 

  138. Van Oers MH, Klasa R, Marcus RE, Wolf M, Kimby E, Gascoyne RD, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006;108:3295–301.

    Article  CAS  PubMed  Google Scholar 

  139. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, et al. A new prognostic index (MIPI) for patients with advanced mantle cell lymphoma. Blood. 2008;111:558–65.

    Article  CAS  PubMed  Google Scholar 

  140. Rummel M, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, muticentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203–10.

    Article  CAS  PubMed  Google Scholar 

  141. Romaguera JE, Fayad L, Rodriguez MA, Broglio KR, Hagemeister FB, Pro B, et al. High rate of durable remission after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus Hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol. 2005;23:7013–23.

    Article  CAS  PubMed  Google Scholar 

  142. Wang L, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibruitinib in relapsed or refractory mantle cell lymphoma. N Engl J Med. 2014;369:507–16.

    Article  CAS  Google Scholar 

  143. Thomas DA, Faderl S, O’Brien S, Bueso-Ramos C, Cortes J, Garcia-Manero G, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106(7):1569–80.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Hacettepe University Institute of Cancer, Sıhhiye, Ankara, Turkey

    Alma Aslan, Serkan Akın, Taner Babacan & Evren Özdemir

Authors
  1. Alma Aslan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Serkan Akın
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Taner Babacan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Evren Özdemir
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Hacettepe University Institute of Cancer, Sihhiye, Ankara, Turkey

    Suayib Yalcin

  2. Department of Oncology, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

    Philip A. Philip

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Aslan, A., Akın, S., Babacan, T., Özdemir, E. (2019). Gastrointestinal Lymphomas. In: Yalcin, S., Philip, P. (eds) Textbook of Gastrointestinal Oncology. Springer, Cham. https://doi.org/10.1007/978-3-030-18890-0_19

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-18890-0_19

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-18888-7

  • Online ISBN: 978-3-030-18890-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation